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Abstract	  
	  
The	   past	   years	   have	   seen	   an	   increase	   in	   the	   use	   of	   a	   gluten-­‐free	   diet	   (GFD)	  
outside	  a	  diagnosis	  of	  coeliac	  disease	  (CD)	  or	  wheat	  allergy	  (WA).	  This	  trend	  has	  
led	   to	   the	   identification	   of	   a	   new	   clinical	   entity	   termed	   non-­‐celiac	   gluten	  
sensitivity	   (NCGS),	   which	   has	   clinical	   features	   that	   overlap	   with	   those	   two	  
previously	  mentioned.	  The	  onset	  of	  symptoms	  in	  patients	  with	  NCGS	  can	  occur	  
within	  hours	  or	  days	  of	  gluten	  ingestion	  and	  the	  prevalence	  of	  NCGS	  is	  estimated	  
to	   round	  6%.	  The	  pathophysiologic	  process	   is	   thought	   to	  be	   through	  an	   innate	  
immune	   mechanism,	   whereas	   CD	   and	   WA	   are	   autoimmune-­‐	   and	   allergen-­‐
mediated,	   respectively.	   However,	   NCGS	   is	   not	   without	   its	   controversies	   and	  
uncertainties,	   in	   particular	   pertaining	   to	   whether	   it	   is	   gluten	   or	   non-­‐gluten	  
components	   of	   the	   grain	   evoking	   symptoms;	   evidence	   suggests	   that	   dietary	  
triggers	   other	   than	   gluten,	   such	   as	   FODMAPs	   (fermentable	   oligosaccharides,	  
disaccharides,	   monosaccharides,	   and	   polyols),	   as	   well	   as	   amylase-­‐trypsin	  
inhibitors	  may	  be	   implicated.	  Moreover,	  emerging	  evidence	  suggests	  that	  NCGS	  
can	  be	  associated	  with	  other	  gastrointestinal	  pathologies	  such	  as	  irritable	  bowel	  
syndrome	  (IBS).	  
Currently,	  no	  specific	   laboratory	  biomarkers	  are	  available	  to	  diagnose	  NCGS.	  
Exclusion	  of	  CD	  and	  WA	  is	  necessary	  in	  the	  evaluation	  of	  a	  patient	  suspected	  to	  
have	   NCGS,	   followed	   by	   an	   elimination	   diet	   of	   gluten-­‐containing	   foods	   to	  
evaluating	   whether	   health	   improves	   and	   a	   monitored	   open	   challenge	   to	  
document	   the	   recurrence	   of	   gastrointestinal	   and/or	   extraintestinal	   symptoms	  
associated	  with	  the	  reintroduction	  of	  gluten.	  However,	  one	  should	  bear	  in	  mind	  
that	  most	  patients	   suspected	   to	  have	  NCGS	  have	  already	   initiated	  a	  GFD	  at	   the	  
time	  of	  an	  evaluation.	  
Additional	   research	   studies	   as	   well	   as	   novel	   techniques	   that	   might	   help	  
diagnose	  NCGS	  in	  the	  future	  are	  essential	  to	  promote	  a	  better	  understanding	  of	  




Abbreviations	  and	  Acronyms	  
GFD:	   gluten-­‐free	   diet;	   CD:	   coeliac/celiac	   disease;	   WA:	   wheat	   allergy;	   NCGS:	  
non-­‐celiac	  gluten	  sensitivity;	  FODMAP/FODMAPs:	  fermentable	  oligosaccharides,	  
disaccharides,	  monosaccharides,	  and	  polyols;	  IBS:	  irritable	  bowel	  syndrome,	  GS:	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Resumo	  
	  
Nos	   últimos	   anos,	   têm-­‐se	   observado	   uma	   grande	   adesão	   a	   uma	   dieta	   sem	  
glúten,	  em	  situações	  que	  vão	  para	  além	  da	  doença	  celíaca	  ou	  alergia	  ao	  trigo.	  Esta	  
tendência	   tem	   levado	   ao	   reconhecimento	   de	   uma	   nova	   patologia,	   denominada	  
sensibilidade	  ao	  glúten	  não	  celíaca,	  que	  apresenta	  características	  clínicas	  que	  se	  
sobrepõem	  às	  duas	  outras	   condições.	  A	  manifestação	  de	   sintomas	  nos	  doentes	  
com	   sensibilidade	   ao	   glúten	   não	   celíaca,	   pode	   surgir	   dentro	   de	   horas	   ou	   dias	  
após	  a	  ingestão	  do	  glúten	  e,	  estima-­‐se	  que	  a	  prevalência	  da	  doença	  ronde	  os	  6%.	  
Pensa-­‐se	  que	  a	  sua	  fisiopatologia	  se	  deve	  a	  um	  mecanismo	  de	   imunidade	  inata,	  
enquanto	  que	  na	  doença	  celíaca	  e	  na	  alergia	  ao	  trigo,	  o	  mecanismo	  responsável	  é	  
autoimune	  e	  mediado	  por	  alérgeno,	  respetivamente.	  No	  entanto,	  a	  sensibilidade	  
ao	  glúten	  não	  celíaca	  apresenta	  várias	  controvérsias	  e	  incertezas,	  nomeadamente	  
sobre	   se	   é	   o	   glúten	   ou	   outros	   elementos	   dos	   cereais	   que	   provocam	   a	  
sintomatologia.	   Diversas	   evidências	   sugerem	   que	   existem	   outros	   fatores	  
responsáveis	   além	   do	   glúten,	   nomeadamente	   os	   FODMAPs	   (Oligosacarídeos,	  
Dissacarídeos,	  Monosacarídeos	  e	  Polióis	  Fermentáveis)	  e	  os	   inibidores	  amilase-­‐
tripsina.	  Além	  disso,	  estudos	  recentes	  sugerem	  que	  a	  sensibilidade	  ao	  glúten	  não	  
celíaca	   pode	   estar	   associada	   a	   outras	   patologias	   gastrointestinais	   como	   o	  
síndrome	  do	  intestino	  irritável.	  
Atualmente,	  não	  há	  biomarcadores	  laboratoriais	  específicos	  disponíveis	  para	  
diagnosticar	  a	  doença.	  Na	  avaliação	  de	  um	  doente	  com	  suspeita	  de	  sensibilidade	  
ao	  glúten	  não	  celíaca,	  é	   imperativo	  excluir	  a	  doença	  celíaca	  e	  a	  alergia	  ao	  trigo,	  
assim	   como	   instituir	   uma	   dieta	   com	   a	   eliminação	   dos	   alimentos	   que	   contêm	  
glúten,	  para	  se	  avaliar	  se	  existe	  alguma	  melhoria	  clínica	  e,	  posteriormente,	  fazer	  
a	   reintrodução	  do	  glúten,	  para	  documentar	  a	  eventual	   recorrência	  de	  sintomas	  
gastrointestinais	  e	   	  extra-­‐intestinais.	  No	  entanto,	  é	   importante	  salientar	  que,	  na	  
altura	   da	   avaliação,	   a	   maioria	   dos	   doentes	   com	   suspeita	   da	   doença	   já	   terá	  
iniciado	  previamente	  uma	  dieta	  sem	  glúten.	  	  
Estudos	  de	  investigação	  adicionais,	  assim	  como	  a	  aposta	  em	  novas	  técnicas	  de	  
diagnóstico	   da	   doença,	   são	   aspetos	   cruciais	   a	   desenvolver	   no	   futuro.	   A	  
identificação	  de	  biomarcadores	  para	  um	  diagnóstico	  definitivo	  e	  rigoroso	  e	  uma	  
melhor	   compreensão	  da	  doença,	   são	   elementos	   fundamentais	   para	   otimizar	   os	  
cuidados	  aos	  doentes.	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The	  set:	  consumption	  of	  wheat	  in	  the	  world	  
	  
Consumption	  of	  wheat	  has	  increased	  exponentially	  over	  the	  last	  half-­‐century	  
in	   the	   Western	   world,	   becoming	   a	   more	   desirable	   grain	   than	   rice	   in	   large	  
populations	  in	  China	  and	  India.[1]	  	  
10,000	  years	  ago,	  with	   the	  worldwide	  spread	  of	   the	  Mediterranean	  diet,	   the	  
native	   human	   diet	   of	   fruits,	   vegetables,	   fish	   and	   meat	   was	   for	   the	   first	   time	  
introduced	   to	   a	   higher	   exposure	   to	   grain	   and	   gluten-­‐containing	   foods.[2]	  
Nowadays,	  it	  is	  estimated	  that	  the	  mean	  daily	  gluten	  intake	  rounds	  20	  g	  and	  even	  
higher	  in	  some	  Mediterranean	  countries.[3,	  4]	  
However,	   there	   has	   been	   a	   mistrustful	   spreading	   perception	   among	   the	  
general	   public	   that	   eating	   food	   with	   wheat	   or	   other	   gluten-­‐laden	   grains	   is	  
harmful[5]	   and	  may	   lead	   to	  weight	   gain,	   obesity,	   depression,	   anxiety,	   arthritis	  
and	  autism.[6]	  Media	  and	  general	  public	   interest	   in	   this	   topic	   is	  overwhelming.	  
This	   is	   evident	  by	   the	  number	  of	  Google	   to	  Pubmed	  hits	   (~5000:1)	   for	  gluten-­‐
free	  diet	  (GFD).[5]	  
Given	   the	   recent	   increase	   of	   the	   gluten-­‐free	   market	   worldwide,[7]	   an	  
increasingly	   larger	   proportion	   of	   the	   population,	   mainly	   in	   Europe,	   Australia,	  
New	  Zealand	  and	  the	  United	  States[2]	  is	  now	  either	  avoiding	  dietary	  wheat	  foods	  
that	   contain	   gluten	   or	   eliminating	   gluten	   entirely	   from	   their	   diets.[8]	   Every	  
major	  change	  in	  our	  diet	  carries	  with	  it	  the	  possibility	  of	  unforeseen	  risks.	  Wheat	  
avoidance	   can	   have	   a	   huge	   impact	   on	   nutritional	   intake	   (without	   appropriate	  
dietary	   advice)	   and	   quality	   of	   life,	   and	   studies	   investigating	   these	   are	   of	   the	  
utmost	  urgency.[9]	  	  
There	  is	  a	  clear	  need	  of	  “separating	  the	  wheat	  from	  the	  chaff”.[7] 
	  
	  
What	  is	  gluten?	  
	  
‘Gluten’	  is	  a	  complicated	  term	  by	  itself.	  It	  refers	  to	  the	  main	  protein	  complex	  of	  
wheat	  and	  other	  cereals,	  including	  barley,	  rye	  and	  spelt.[10]	  
It	   also	   refers	   to	   the	   glue-­‐ish	  mass	   with	   well-­‐known	   baking	   properties:	   it	   is	  
often	   added	   to	   improve	   product	   characteristics[4]	   as	   it	   provides	   viscosity	   and	  
elasticity,	   forming	   a	   dough	   from	   its	   washing	   starch	   granules	   (which	   is	   named	  
vital	  gluten)	  and	  helping	  food	  products	  to	  rise	  and	  keep	  their	  shape	  and	  chewy	  
texture.[1]	  Depending	  on	  the	  thoroughness	  of	  washing,	  the	  dry	  solid	  has	  75–85%	  
protein	   and	   5–10%	   lipids,	   being	   the	   remainder	   starch	   and	   non-­‐starch	  
carbohydrates.[11]	  
Gluten	  contains	  hundreds	  of	  proteins	  and	  protein	  components	  and	  they	  have	  
been	   conventionally	   divided	   according	   to	   their	   functions	   into	   soluble	   gliadins	  
(that	   contain	  monomeric	   proteins	  which	   provide	   viscosity	   and	   extensibility	   of	  
the	   dough	   system)	   and	   insoluble	   glutenins	   (containing	   aggregated	   proteins	  
which	  contribute	  to	  its	  strength	  and	  elasticity).[12]	  
Amongst	   its	   other	  uses,	   gluten	   can	  also	  be	  used	   in	   cosmetics,	   hair	  products,	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Development	  of	  gluten-­‐related	  pathology	  
	  
Many	   factors	   might	   have	   contributed	   to	   the	   development	   of	   gluten-­‐related	  
pathology[9]	  such	  as	  variations	  in	  individual	  diets	  with	  regard	  to	  a	  higher	  intake	  
of	  gluten-­‐containing	  foods.	  The	  amount	  and	  types	  of	  wheat	  consumed,	  along	  with	  
the	  higher	  gluten	  quantity	  in	  bread	  and	  bakery	  products,	  due	  to	  the	  reduced	  time	  
of	  dough	  fermentation,	  is	  something	  to	  be	  conscious	  about,	  although	  there	  is	  no	  
clear	   evidence	   of	   an	   increase	   in	   the	   gluten	   content	   of	   wheat	   during	   the	   20th	  
century.[1]	  
Nowadays,	  most	  of	   the	  wheat	  products	  we	  consume	  are	  made	   from	  modern	  
wheat	   varieties	   bred	   after	   the	   ‘‘Green	   Revolution”	   (in	   the	   1970s)	   and	   the	  
introduction	  of	  dwarf	  genes	  led	  to	  the	  development	  of	  shorter	  straw	  lines.[14]	  
The	   development	   of	   new	   types	   of	  wheat	  with	   high	   amounts	   of	   toxic	   gluten	  
peptides	   was	   triggered	   by	   the	   mechanization	   of	   farming,	   agronomic	   practices	  
(such	  as	  nitrogen	  fertilization)	  and	  the	  growing	  industrial	  use	  of	  pesticides,[15]	  
having	  led	  to	  substantial	  gains	  in	  productivity	  and	  technological	  quality.[16]	  
The	   variation	   in	   dough	   rheology	   and	   bread-­‐making	   performance	   among	  
wheat	   varieties	   is	   largely	   determined	   by	   its	   protein	   content	   differences,[17]	  
depending	  on	  specific	  gliadins	  and	  high	  molecular	  weight	  glutenin	  subunits.[18]	  
Any	  systematic	  increase	  in	  the	  protein	  content	  of	  wheat	  might	  also	  play	  a	  role	  in	  
non-­‐celiac	   gluten	   sensitivity	   (NCGS),	   as	   the	   average	   slice	   of	   bread	   weighs	  
approximately	  40	  g	  and	  contains	  about	  2.4	  g	  of	  protein,	  1.8	  g	  of	  which	  would	  be	  
gluten.[1]	  
Highly	   sensitive	   diagnostic	   tools	   for	   gluten-­‐induced	   disorders	   have	   also	  
gradually	  improved	  over	  time[9],	  allowing	  for	  the	  identification	  of	  new	  cases	  and	  
one	  cannot	  also	  rule	  out	  the	  process	  by	  which	  the	  immune	  system	  switches	  from	  
tolerance	   of	   wheat	   gluten	   protein	   to	   intolerance,	   describing	   this	   increasingly	  
frequent	  presentation	  to	  primary	  care	  and	  gastroenterologists	  practitioners.[19]	  
	  
	  
Gluten-­‐related	  pathology	  and	  the	  appearance	  of	  NCGS	  
	  
The	  term	  ‘gluten-­‐related	  disorders’	  is	  complicated	  and	  refers	  to	  the	  suggested	  
umbrella	   term	   for	   all	   diseases	   triggered	   by	   gluten.[20]	   The	   development	   of	  
adverse	   reactions	   against	   gluten,	   is	   supposed	   to	   be	   concomitant	  with	   the	   very	  
moment	   humans	   started	   its	   ingestion[21]	   although	   in	   the	   last	   10	   years	   it	   has	  
become	   clear	   that	   there	   are	   distinguished	   clinical	   conditions	   related	   to	   gluten	  
consumption.[22]	  	  
Each	  gluten-­‐related	  disorder	  exhibits	  a	  unique	  pathophysiological	  response	  to	  
gluten	  ingestion,	  though	  they	  may	  maintain	  considerable	  overlap	  in	  their	  clinical	  
presentation.[2]	  Among	  them	  are:	  wheat	  allergy	  (WA),	  an	  autoimmune	  form	  that	  
includes	  coeliac	  disease	  (CD),	  dermatitis	  herpetiformis,	  gluten-­‐related	  ataxia	  and	  
peripheral	   neuropathy[9]	   and	   NCGS,	   which	   is	   possibly	   immune-­‐mediated	   and	  
currently	  the	  most	  common.[22]	  
	  
Hemmings,	  Ellis	  and	  Linaker	  incorrectly	  used	  the	  term	  NCGS	  for	  the	  first	  time	  
in	   1978,	   in	   WA	   patients	   that	   presented	   abdominal	   pain	   and	   diarrhea,	   which	  
remitted	  after	  gluten	  withdrawal.[24]	  Only	  in	  1980	  was	  this	  entity	  considered	  a	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syndrome[25]	   after	   several	   cases	   in	  which	   non-­‐CD	   or	  WA	   patients’	   symptoms	  
dramatically	  disappeared	  after	  gluten	  withdrawal	  from	  diet.	  	  
In	   2010,	   Sapone	   et	   al.,	   described	   the	   clinical	   and	   diagnostic	   features	   of	   this	  
condition	  and	  a	  First	  Expert	  Meeting	  was	  held	   in	  London	  in	  2011,	   to	  develop	  a	  
consensus	   on	   new	   nomenclature	   and	   classification	   of	   gluten-­‐related	   disorders.	  
Since	   then,	  many	   names	   have	   been	   suggested	   for	   this	   disorder,	   such	   as	   gluten	  
sensitivity	  (GS),	  gluten	  hypersensitivity	  or	  non-­‐celiac	  gluten	  intolerance.[26]	  The	  
“labeling”	  of	  this	  disorder	  has	  been	  a	  matter	  of	  massive	  debate	  among	  the	  panel	  
experts,	   reflecting	   the	   poor	   knowledge	   of	   the	   pathophysiology	   of	   this	  
condition,[7]	   and	  only	   after	   a	   Second	  Expert	  Meeting	  on	  GS,	   held	   in	  Munich	   in	  
2012,	   was	   its	   current	   name,	   NCGS,	   provisionally	   defined	   in	   order	   to	   avoid	  
confusion	  with	  similar	  conditions.[7,	  8]	  Nonetheless,	   its	  definition	  still	   requires	  
refinement	  in	  the	  future.[27]	  
	  
NCGS	   apparently	   involves	   neither	   the	   allergic	   nor	   autoimmune	  mechanisms	  
nor	  a	   specific	  genetic	  background.	   It	   can	  be	  diagnosed	   in	   those	  patients	  with	  a	  
reaction	   to	   gluten,	   with	   a	   confirmed	   absence	   of	   allergic	   or	   autoimmune	  
mechanisms	   after	   appropriate	   laboratory	   testing	   such	   as	   celiac-­‐specific	  
antibodies	   and	   classical	   celiac	   villous	   atrophy	   lesions	   in	   the	   duodenal	  
mucosa.[28]	   It	   may	   be	   caused	   by	   improper	   immune	   responses,	   intolerance	   to	  






Amongst	   gluten-­‐related	   pathology,	   WA	   is	   the	   least	   common	   of	   them	   all,	  
affecting	   about	   1%	   if	   the	   population	   and	   being	   less	   prevalent	   than	   CD.[8]	   It	   is	  
defined	   as	   an	   acute	   anaphylactic	   condition,[10]	   an	   adverse	   immunological	  
reaction	   (immunoglobulin	   E-­‐	   and	   non-­‐immunoglobulin	   E-­‐mediated)	   to	   gluten	  
and	  other	  proteins	  found	  in	  wheat.[1]	  It	  is	  the	  cross-­‐linking	  of	  immunoglobulin	  E	  
by	   repeat	   sequences	   in	   gluten	   peptides	   (for	   example,	   serine-­‐glutamine-­‐
glutamine	   -­‐glutamine-­‐(glutamine-­‐)proline-­‐proline-­‐phenylalanine)	   that	   triggers	  
the	   release	  of	   chemical	  mediators,	   such	  as	  histamine,	   from	  basophils	   and	  mast	  
cells[12]	  and	  diagnosis	  is	  made	  by	  skin	  prick	  test	  and	  invitro	  immunoglobulin	  E	  
assays.	   Depending	   on	   the	   route	   of	   allergen	   exposure	   and	   the	   underlying	  
immunological	  mechanisms,	   it	   clinically	  manifests	  as	  either	   classic	   food	  allergy	  
(affecting	   the	   skin,	   gastrointestinal	   and	   respiratory	   tract),	   wheat-­‐dependent	  
exercise-­‐induced	   anaphylaxis,	   occupational	   asthma	   (so-­‐called	   baker’s	   asthma)	  





CD	   is	   an	   autoimmune	   inflammatory	   disorder	   of	   the	   small	   intestinal	  
mucosa,[10]	  with	  a	  strong	  genetic	  basis,	  positively	  correlated	  with	  specific	  HLA	  
(human	   leukocyte	   antigen)-­‐DQ	   gene	   pairs	   and	   potentially	   triggered	   by	   other	  
environmental	   factors.[29]	   It	   affects	   roughly	   1%	  of	   the	   general	   population[30]	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and	   it	  has	  specific	   serologic	  markers,	   comprising	   immunoglobulin	  A	  antibodies	  
to	   the	   enzyme	   tissue	   transglutaminase	   (IgA	   tTG2)	   or	   immunoglobulin	   A	   and	  
immunoglobulin	   G	   deamidated	   gliadin	   peptide	   antibodies.[10,	   31]	   Endomysial	  
antibody	  testing	  (IgA	  endomysial)	  also	  seems	  to	  have	  a	  high	  predictive	  value	  for	  
the	  future	  development	  of	  CD.[29,	  32,	  33]	  
Its	   pathophysiology	   stars	   once	   ingested	   gluten	   is	   degraded	   into	   relatively	  
proline-­‐rich	   fragments,	   binding	   to	   disease	   predisposing	   HLA	   molecules,	   that	  
bound	   to	   specific	   CD4	   T	   cells,[34]	   leading	   to	   intestinal	   villous	   atrophy	   and	  
increased	   intestinal	   permeability.	   Gastrointestinal	   symptoms	   include	   those	  
associated	  with	  malabsorption	   in	   the	   small	   intestine	   of	   the	   affected	   individual,	  
such	  as	  chronic	  diarrhoea,	  bloating,	  abdominal	  distension,	  chronic	  constipation	  
and	  weight	  loss.[35]	  
	  
	  
Prevalence	  of	  non-­‐celiac	  gluten	  sensitivity	  
	  
Its	   frequency	   in	   the	   general	   population	   is	   still	   uncertain	   and	   difficult	   to	  
estimate,	  as	  many	  patients	  are	  currently	  self-­‐diagnosed	  and	  start	  a	  GFD	  without	  
any	  medical	  advice	  or	  consultation.[36]	  Although	  there	  is	  evidence	  of	  NCGS	  cases	  
in	  adults	  since	  the	  20th	  century,	  the	  first	  cases	  in	  children	  were	  only	  described	  in	  
2012.[37]	  
Epidemiological	  data	  has	  been	  generated	   to	  help	   establish	   the	  magnitude	  of	  
the	  problem	  and	  according	   to	   studies	   that	   cover	   approximately	   the	   last	  half	   of	  
the	  20th	  century,[1]	  it	  seems	  clear	  that	  in	  recent	  years	  it	  has	  rapidly	  increased	  in	  
adults[3]	  and	  in	  children.[37]	  From	  a	  2010	  report	  with	  a	  possible	  prevalence	  of	  
NCGS	  of	  0.55%,[30]	  it	  is	  now	  estimated	  that	  the	  real	  prevalence	  can	  be	  as	  high	  as	  
6%,[10]	  affecting	  more	  females	  (male-­‐to-­‐female	  ratio	  of	  1:3)	  and	  young/middle	  
age	  adults,	   in	   the	  absence	  of	   identified	  risk	   factors.[30,	  38,	  39]	  However,	  when	  
explored	   in	   a	   selected	   setting	  of	   patients	   affected	  by	   irritable	  bowel	   syndrome	  
(IBS),	   the	   prevalence,	   as	   proved	   through	   a	   double-­‐blind	   placebo-­‐controlled	  
challenge,	  reached	  28%.[23]	  
	  
	  
Pathophysiology	  of	  non-­‐celiac	  gluten	  sensitivity	  
	  
Antigen-­‐presenting	  cells	  
NCGS	   has	   many	   grey	   areas	   concerning	   its	   pathophysiology	   and	   it	   remains	  
largely	   undetermined,	   but	   it	   is	   recognized	   that	   gluten	   and	   its	   related	  peptides,	  
namely	  undigested	  or	   partly	   digested	   gliadin,	   can	   stimulate	  dendritic	   cells	   and	  
induce	  an	  innate	  immune	  response.[12]	  
This	  enhanced	  innate	  immune	  response	  is	  immediate	  and	  fast,	  including	  both	  
cellular	  and	  humoral	  components,	  affecting	  a	  wide	  range	  of	  human	  cell	  functions.	  
	  
Reduced	  intestinal	  permeability	  
However,	   unlike	   CD	   there	   seems	   to	   be	   no	   enhanced	   intestinal	   permeability	  
and	   levels	   of	   tight	   junction	   protein	   levels	   between	   epithelial	   cells	   remain	  
intact.[30]	   A	   significant	   reduction	   in	   T-­‐regulatory	   cell	   markers	   has	   also	   been	  
Non-­‐celiac	  gluten	  sensitivity	  
-­‐	  A	  real	  disease?-­‐	  
	  
	   9	  
found	  in	  NCGS	  compared	  to	  CD	  patients,	  which	  can	  be	  interpreted	  as	  a	  reduced	  
activation	  of	  adaptive	  immunity.[9,	  21]	  
Furthermore,	  NCGS	  subjects	  who	  go	  through	  a	  lactulose/mannitol	  absorption	  
test	   display	   a	   reduced	   intestinal	   permeability,	   which	   goes	   in	   line	   with	   the	  
hypothetical	   reduced	   permeability	   of	   the	   intestinal	   barrier	   in	   NCGS.[9]	   This	  
hypothesis	   has	   already	   been	   questioned	   by	   Biesekierski	   et	   al.,	   who	   despite	  
showing	   that	   patients	   with	   NCGS	   truly	   develop	   symptoms	   when	   eating	  
gluten,[20]	   did	   not	   find	   any	   significant	   difference	   in	   the	   intestinal	   barrier	  
function	   of	   two	   randomly	   treated	   groups	   of	   NCGS	   patients	   (one	   challenged	   by	  
gluten,	   the	   other	   by	   placebo)	   using	   the	   dual	   sugar	   absorption	   test.[36]	  
Controversially,	   Vazquez-­‐Roque	   et	   al.	   have	   documented	   increased	   intestinal	  
permeability	  in	  a	  subgroup	  of	  HLA-­‐DQ2/DQ81	  NCGS	  patients	  with	  IBS,	  diarrhea	  
and	  GS.[9]	  	  
	  
Adaptive	  immunity	  markers	  
Also,	  several	  studies	  have	  confirmed	  the	  central	  role	  of	  adaptive	  immunity	  in	  
the	   development	   of	   CD	   by	   showing	   systemic	   and	   mucosal	   expression	   of	  
cytokines	   associated	   with	   Th1	   and	   Th17	   responses,	   contrasting	   with	   NCGS	  
patients	  where	  adaptive	  immunity	  markers	  such	  as	  IL-­‐17A,	  IL-­‐6,	  interferon-­‐c,	  IL-­‐
17	   and	   IL-­‐21	   have	   not	   been	   increased	   in	   intestinal	   biopsies.	   Moreover,	   NCGS	  
patients	  have	   an	   increase	   in	   the	  α	   and	  β	   classes	  of	   intraepithelial	   lymphocytes	  
with	  no	  increase	  in	  adaptive	  immunity-­‐related	  gut	  mucosal	  gene	  expression.[21]	  
These	   studies	   suggest	   an	   important	   role	   of	   the	   intestinal	   innate	   immune	  
system	  in	  the	  pathogenesis	  of	  NCGS	  without	  an	  adaptive	  immune	  response.[30]	  
	  
HLA-­‐DQ2	  and	  -­‐DQ8	  
Unlike	   duodenal	   mucosa	   from	   CD	   patients	   exposed	   to	   gliadin	   in-­‐vitro,	  
intestinal	  mucosa	   from	  NCGS	  patients	  do	  not	  express	  markers	  of	   inflammation.	  
New	  insights	  to	  explain	  the	  pathogenic	  mechanisms	  of	  NCGS	  have	  been	  provided	  
by	   HLA-­‐DQ8	   transgenic	   mice	   sensitized	   to	   gliadin	   hypothesizing	   that	  
neuromuscular	   dysfunction	   and	   gut	   microbiota	   could	   have	   a	   role	   in	   gluten-­‐
induced	  symptoms.[9]	  Genetic	  predisposition	  to	  CD	  has	  also	  been	  suggested	  as	  a	  
factor	  for	  NCGS	  where	  patients	  carrying	  the	  HLA-­‐DQ2	  allele,	  but	  without	  villous	  




Furthermore,	   recent	  studies	  have	  shown	  that	  gluten	  and	   its	  related	  proteins	  
are	   not	   the	   only	   triggers	   of	   NCGS	   and	   that	   other	   molecules	   also	   contained	   in	  
wheat	   likely	   play	   a	   relevant	   role	   in	   causing	   this	   syndrome,	   namely	   amylase–
trypsin	  inhibitors.[41]	  Another	  component	  in	  wheat,	  wheat	  lectin	  agglutinin,	  has	  
also	   shown	   increased	   intestinal	   permeability	   and	   potential	   activation	   of	   the	  
immune	  system,	  but	  needs	  further	  clinical	  studies	  to	  establish	  the	  its	  pathogenic	  
role	  in	  humans.[40]	  	  
	  
Opioid-­‐like	  activity	  of	  gluten	  
Others	   studies	  have	  also	  shown	   that	  another	   factor	   that	   could	  play	  a	   role	   in	  
NCGS	  development	  could	  be	  the	  opioid-­‐like	  activity	  of	  gluten.	  Gluten	  proteins	  can	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mimic	   some	   of	   the	   effects	   of	   opiates	   by	   altering	   the	   intestinal	   transit	   time	   in	  
healthy	  volunteers	  in	  a	  naloxone-­‐reversible	  manner.[9]	  
	  
Multiple	  food	  hypersensitivities	  and	  FODMAPs	  	  
Many	  patients	  with	  NCGS	  display	  multiple	   food	  hypersensitivities	   and	   some	  
authors	  believe	   that	   this	   could	   in	  part	  be	   related	   to	   the	  physiological	  effects	  of	  
FODMAPs:	   Fermentable	  Oligosaccharides,	   Disaccharides,	  Monosaccharides	   And	  
Polyols.[40]	  
A	   diet	   rich	   in	   poorly	   absorbed	   and	   fermentable	   short-­‐chain	   carbohydrates	  
induces	  intestinal	  lumen	  distension	  (osmotic	  activity	  of	  liquid	  and	  gas	  occurs	  due	  
to	   their	   small	   molecular	   size)	   and	   rapid	   fermentation	   in	   the	   colon,	   leading	   to	  
functional	   and	   unspecific	   gastrointestinal	   symptoms	   (especially	   bloating).[21,	  
40]	  
Therefore,	   NCGS	   might	   be	   confused	   with	   FODMAP	   sensitivity,	   and	   gluten	  
might	   be	   only	   a	   cofactor	   (or	   a	   confounder)	   when	   looking	   for	   the	   origin	   of	  
gastrointestinal	   symptoms.[21,	   42,	   43]	   In	   a	   study,	   many	   self-­‐perceived	   NCGS	  
patients	  still	  had	  significant	  symptoms	  despite	  a	  GFD	  and	  there	  was	  significant	  
improvement	  of	  gastrointestinal	  symptoms	  by	  following	  a	  low	  FODMAP	  diet	  for	  
two	  weeks.[40]	  In	  fact,	  the	  literature	  suggests	  that	  FODMAPs	  and	  not	  gluten	  per	  
se	   are	   the	   triggers	  of	  gastrointestinal	   symptoms	   in	  patients	   that	   fit	  most	  of	   the	  
proposed	  NCGS	  definitions.	  Interestingly,	  wheat,	  rye,	  and	  barley	  are	  food	  sources	  
of	  FODMAPs	  and	  should	  be	  avoided	  in	  FODMAP	  sensitive	  individuals.[33]	  
However,	   functional	   gastrointestinal	   symptoms	   in	   NCGS	   as	   well	   as	   other	  
disorders,	   could	   also	   be	   partly	   related	   to	   food	   additives,	   such	   as	   glutamates,	  
benzoates,	   sulfites	   and	   nitrates,	   which	   are	   added	   to	   commercial	   products	   to	  
improve	  flavour,	  colour	  and	  for	  preservation.	  In	  general,	  the	  stronger	  the	  flavor	  
of	   the	  food,	   the	  higher	  the	  chemical	  content	  will	  be.	  Food	  chemicals	  add	  strong	  
afferent	   stimuli	   to	   the	   enteric	   nervous	   system	   and	   food-­‐induced	  modifications	  
can	   target	   the	   brain	   through	   the	  microbiota-­‐brain-­‐gut	   axis.[42]	  When	   patients	  
display	   visceral	   hypersensitivity,	   normal	   physiological	   stimulation	   by	   such	  
chemicals	   may	   result	   in	   exaggerated	   effector	   responses	   leading	   to	   luminal	  
distension.	  Consequently,	   a	   low-­‐FODMAP	  diet	   can	  be	  a	   realistic	   and	  efficacious	  
attempt	  for	  improving	  gastrointestinal	  symptoms	  in	  NCGS	  patients.[9,	  40]	  
	  
Nocebo	  effect	  
Finally,	   it	   must	   be	   emphasized	   that	   in	   some	   circumstances	   NCGS	   is	   an	  
imaginary	  ailment	  caused	  by	  the	  nocebo	  effect	  (the	  adverse	  reaction	  experienced	  
by	  a	  patient	  who	  receives	  such	  a	  therapy)	  of	  gluten	  ingestion.	  This	  possibility	  in	  
patients	   with	   a	   self-­‐diagnosis	   of	   food	   hypersensitivity	   has	   clearly	   been	  
established	   by	   double-­‐blind	   trials.	   The	   placebo	   effect	   of	   the	   elimination	   diet	   is	  
generally	  regarded	  as	  superior	  to	  that	  of	  drug	  treatment.[9]	  
	  
	  
A	  real	  disease?	  
	  
Symptoms	  alone	  cannot	  reliably	  differentiate	  WA	  and	  CD	  from	  NCGS,	  as	  there	  
is	  often	  substantial	  overlap	  in	  symptoms	  between	  conditions,[31]	  hence	  the	  need	  
Non-­‐celiac	  gluten	  sensitivity	  
-­‐	  A	  real	  disease?-­‐	  
	  
	   11	  
to	   perform	   serological	   and	   histological	   objective	   tests	   as	   well	   as	   HLA-­‐DQ	  
typing.[44]	  
Before	  2000,	  only	   two	  papers	  reported	  of	   the	  possible	  existence	  of	  NCGS.	   In	  
1980,	   in	   a	   double-­‐blind	   crossover	   trial,	   Cooper	   et	   al.	   reported	   six	   of	   eight	   GS	  
cases	   in	  women	  complaining	  of	  abdominal	  pain,	  bloating	  and	  diarrhea,	  without	  
any	  serological	  or	  histological	  evidence	  of	  CD.[25,	  26]	  Later	  in	  2000,	  Kaukinen	  et	  
al.	  reported	  that	  63%	  of	  94	  adults,	  that	  did	  not	  satisfy	  the	  diagnostic	  criteria	  for	  
CD	   and	   WA,	   complained	   of	   abdominal	   symptoms	   after	   gluten	   ingestion	   and	  
benefited	  from	  a	  GFD.[45]	  
In	  2008,	  another	  study	  showed	  that	  after	  gluten	  withdrawal,	  gastrointestinal	  
symptoms	   improved	   in	   64.7%	   of	   CD	   patients	   and	   75.0%	   of	   non-­‐CD	   patients,	  
followed	  by	  clinical	  exacerbation	  in	  71.4%	  of	  CD	  patients	  and	  54.2%	  of	  non-­‐CD	  
patients	  with	  gluten	  re-­‐introduction.[46]	  
Gastroenterologists	  and	  allergologists	  at	  the	  time,	  without	  evidence	  to	  explain	  
the	   symptoms,	   did	   not	   treat	   these	   patients	   and	   advised	   them	   to	   continue	  
integrating	   gluten	   into	   their	   diet,	   as	   gluten	  was	  not	   thought	   to	  be	   the	   cause	  of	  
their	  condition.	  In	  most	  cases,	  patients	  were	  regarded	  as	  suffering	  from	  mental	  
disorders	  and	  were	  frequently	  referred	  to	  psychiatrists.	  Even	  nowadays,	  there	  is	  
a	   tendency	   by	   some	   to	   attribute	   NCGS	   presentation	   to	   placebo	   effect	   or	  
somatization,	  particularly	  as	   the	  diagnosis	   is	  based	  on	  subjective	  self-­‐reporting	  
by	  patients.[39,	  47]	  Many	  patients	  are	  deeply	  influenced	  by	  the	  fact	  that	  GFD	  is	  
the	   latest	  diet	   craze	  embraced	  by	  many	  celebrities	  and	   there	   is	   a	  possibility	  of	  
displaying	  an	   imaginary	  syndrome	  with	  a	  subjective	  sensation	  of	   improvement	  
due	  to	  the	  placebo	  effect	  of	  gluten	  withdrawal.[5,	  9]	  The	  self-­‐reported	  prevalence	  
of	  NCGS	  was	  13%	  in	  a	  United	  Kingdom	  population	  questionnaire-­‐based	  survey,	  
with	  less	  than	  1%	  subjects	  having	  a	  medical	  diagnosis	  of	  the	  condition.[23]	  
There	  has	  also	  been	  presented	  an	  association	  with	  fibromyalgia	  and	  diarrhea-­‐
predominant	  IBS.[12]	  However,	  patients’	  symptoms	  significantly	  improved	  when	  
similar	   dietary	   changes	   were	   made[38],	   with	   no	   difference	   regarding	  
neuropsychiatric	   symptoms[48,	   49]	   such	   as	   personality	   traits,	   anxiety	   and	  
depression,	   therefore	   suggesting	   NCGS	   to	   be	   a	   credible	   physical	   diagnosis.[42,	  
47,	  50]	  	  
Placebo	   effect	   induced	   by	   gluten	   withdrawal	   cannot	   be	   unambiguously	  
excluded[51]	   although	   studies	   with	   double-­‐blind	   placebo-­‐controlled	   challenge	  
trials	   already	   showed	   recurrence	   and	   a	   significant	   worsening	   of	   clinical	  
symptoms	  in	  gluten	  vs.	  the	  placebo	  group.[27,	  36]	  
Although	  NCGS	  cannot	  be	  definitively	  diagnosed	  at	  this	  time	  in	  the	  absence	  of	  
objective	  specific	  markers	  and	  cases	  remain	  highly	  presumptive[9],	  a	  diagnosis	  
of	   NCGS	   should	   be	   considered	   when	   patients[41]	   experience	   symptoms	   upon	  




Signs	  and	  symptoms	  
	  
The	   majority	   of	   symptoms	   experienced	   by	   these	   patients	   are	   subjective[5]	  
and	  may	  resemble	  those	  associated	  with	  CD	  and	  WA.	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Gastrointestinal	   symptoms	   include	   abdominal	   pain,	   bloating/abdominal	  
distension,	   flatulence,	   nausea,	   diarrhea,	   but	   there	   is	   a	   prevalence	   of	  
extraintestinal	   symptoms.	   It	   is	   common	   to	   find	   general	   symptoms	   such	   as	  
headaches,	   migraines,	   bone	   or	   joint	   pain,	   muscle	   cramps,	   tingling	   and/or	  
numbness	  in	  the	  legs,	  arms	  or	  fingers,	  brain	  fog,	  chronic	  fatigue	  and	  weight	  loss;	  
dermatological	   symptoms	   such	   as	   eczema,	   erythema	  or	   rashes;	   haematological	  
symptoms	   like	   anemia;	   dental	   signs	   such	   as	   chronic	   ulcerative	   stomatitis;	  
behavioural	  disturbances	  such	  as	  mood	  changes,	  depression	  or	  hyperactivity.[5,	  
8,	  12,	  52]	  
Several	   studies	   suggest	   a	   relationship	   between	   NCGS	   and	   neuropsychiatric	  
disorders,	   particularly	   autism	   and	   schizophrenia[9,	   53,	   54],	   reporting	   patients	  
the	   development	   of	   severe	   neurological	   symptoms	   like	   hallucinations	   and	  
cerebellar	  ataxia,	  although	  these	  lack	  strong	  evidence.[55,	  56]	  
It	   is	   yet	   to	   be	   proven	   if	   and	   how	   gluten	   has	   direct	   causal	   effects	   on	   extra-­‐
intestinal	  symptoms	  in	  patients	  without	  CD.[40]	  
	  
Figure	  1	  -­‐	  Key	  characteristics	  of	  patients	  with	  NCGS	  and	  the	  astronomical	  system	  of	  gluten-­‐related	  disorders.	  Beyond	  the	  
autoimmune	  planet	  of	  CD,	  and	  related	  satellites,	  i.e.	  dermatitis	  herpetiformis	  (DH)	  and	  gluten	  ataxia	  (GA),	  other	  identified	  planets	  include	  
WA,	  NCGS,	  and	  subgroups	  of	  patients	  affected	  with	  autism	  and	  IBS	  [57]	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Diagnostic	  criteria	  &	  management	  
	  
There	  have	  been	  proposed	  several	  algorithms	  for	  the	  differential	  diagnosis	  of	  
gluten-­‐related	  disorders,	  including	  WA,	  CD	  and	  NCGS.	  Based	  on	  a	  combination	  of	  
clinical,	   biological,	   genetic	   and	   histological	   data,	   it	   is	   possible	   to	   differentiate	  
these	  three	  conditions.[12]	  
To	  this	  moment,	  there	  are	  no	  specific	  laboratory	  biomarkers	  for	  NCGS,	  which	  
is	   still	   a	  major	   limitation	   of	   clinical	   studies,	   making	   it	   difficult	   to	   differentiate	  
NCGS	  from	  other	  gluten	  related	  disorders.	  Therefore,	  it	  is	  essentially	  a	  diagnosis	  
of	  exclusion[22]	  and	   the	  diagnosis	   relies	  on	   the	  accurate	  assessment	  of	   clinical	  
features	  along	  with	  the	  exclusion	  of	  WA	  and	  CD[9]	  followed	  by	  an	  open	  challenge	  
to	  evaluate	  whether	  health	  improves	  with	  the	  elimination	  or	  reduction	  of	  gluten	  
from	  the	  patient’s	  diet.	  
	  
Patients	   suspected	   of	   suffering	   from	   a	   gluten-­‐related	   disorder	   should	  
preliminarily	   undergo	   a	   full	   clinical	   and	   laboratory	   evaluation	   to	   exclude	   both	  
WA	   and	   CD,	   using	   appropriate	   tests	   performed	   under	   a	   gluten-­‐containing	  
diet.[42]	   If	   a	   patient	   with	   true	   CD	   has	   been	   following	   a	   GFD,	   they	   may	   have	  
reversals	   in	   pathologic	   and	   laboratory	   findings,	  making	   it	   harder	   to	   confirm	   a	  
diagnosis.[28]	  In	  fact,	  the	  main	  bias	  is	  caused	  by	  the	  absence	  of	  a	  clear	  diagnostic	  
flowchart	   for	   NCGS	   as	   all	   the	   studies	   simply	   enrolled	   patients	   clinically	  
responding	   to	   a	   period	   of	   gluten-­‐free	   dieting	   without	   excluding	   the	   placebo	  
effect.[40]	  
	  
Table	  1	  -­‐	  Comparison	  between	  gluten	  related	  disorders.	  tTG	  (tissue	  transglutaminase),	  EMA	  (endomysium	  antibodies),	  DGP	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Testing	  for	  serum	  immunoglobulin	  E	  antibodies	  to	  gluten	  and	  wheat	  fractions	  
as	  well	  as	  skin-­‐prick	  tests	  should	  rule	  out	  WA,	  whereas	  CD	  must	  be	  excluded	  by	  
the	   absence	   of	   specific	   serological	   tests,	   such	   as	   immunoglobulin	   A	   tTGA,	  
immunoglobulin	   A	   EmA	   and	   immunoglobulin	   G	   deamidated	   gliadin	   peptide	  
antibodies.	   Furthermore,	   a	   duodenal	   biopsy	   is	   highly	   recommended	   in	  
suspicious	  patients	  when	  on	  a	  gluten-­‐containing	  diet,	   in	  order	   to	  rule	  out	  a	  CD	  
diagnosis,	   because	   in	   1–2%	   of	   the	   total	   cases	   of	   CD,	   the	   celiac	   serology	   is	  
negative.[58]	  
Compared	   with	   CD	   patients,	   around	   60%	   of	   NCGS	   patients	   have	   a	   normal	  
histology	   of	   duodenal	   mucosa	   with	   a	   much	   lower	   number	   of	   intraepithelial	  
lymphocytes,	   there	   is	   not	   an	   increase	   of	   T-­‐cell	   receptor	   γ/δ	   intraepithelial	  
lymphocytes,	  and	  class	  II	  MHC	  haplotype	  HLA-­‐DQ2	  and/or	  HLA-­‐DQ8	  are	  present	  
in	   only	   about	   50%	   of	   patients	   (versus	   being	   present	   in	   almost	   all	   CD	  
patients).[12]	  
The	   only	   serological	   marker	   found	   in	   patients	   with	   NCGS	   is	   the	   first-­‐
generation	  antibody	  to	  gliadin	  (AGA)	  and	  studies	  report	  an	  AGA	  immunoglobulin	  
G	   prevalence	   of	   56%	   in	   NCGS	   patients	   and	   a	   much	   lower	   prevalence	   of	   8%	  
regarding	  AGA	  immunoglobulin	  A.[9,	  59,	  60]	  
	  However,	  it	  cannot	  be	  considered	  a	  reliable	  marker	  as	  AGA	  immunoglobulin	  G	  
disappeared	   in	   most	   NCGS	   patients	   within	   6	   months	   of	   initiating	   a	   GFD	   and	  
remained	   positive	   in	   about	   half	   of	   CD	   patients	   after	   gluten	   withdrawal.	   A	  
hypothesis	   that	   immunological	  memory	  might	  be	  active	   in	  CD	  but	  not	   in	  NCGS	  
has	  been	  suggested	  so	  far.[9]	  
The	  marker	  is	  also	  not	  specific	  for	  the	  condition,	  as	  they	  can	  be	  found	  in	  many	  
others,	  such	  as	  autoimmune	  liver	  diseases,	  IBS,	  connective	  tissue	  disorders	  and	  
even	  blood	  donors.[9]	  
	  
Recently,	  a	  NCGS	  Diagnostic	  Protocol	  has	  been	  suggested.	  Its	  aim	  is	  to	  assess	  
the	  clinical	  response	  to	  an	  elimination	  diet	  of	  gluten-­‐containing	  foods,	   the	  GFD,	  
evaluating	  whether	  health	  improves	  with	  the	  elimination	  or	  reduction	  of	  gluten	  
from	  the	  patient’s	  diet,	  and	  to	  measure	  the	  effect	  of	  reintroducing	  gluten	  after	  a	  
period	  of	  treatment	  with	  the	  GFD	  for	  a	  potential	  management.[47]	  
The	   diet	   can	   only	   be	   started	   in	   the	   patient	   who	   is	   on	   a	   normal,	   gluten-­‐
containing	  diet	  for	  at	  least	  six	  weeks,	  although	  a	  simplified/shortened	  diagnostic	  
procedure	  may	   be	   adopted	   in	   patients	   that	   are	   already	   on	   the	   GFD	  when	   first	  
seen	  at	  a	  specialty	  clinic.	  	  
Baseline	   symptoms	   are	   established	   through	   a	   modified	   version	   of	   the	  
Gastrointestinal	   Symptom	   Rating	   Scale	   (GSRS),	   which	   also	   includes	   extra-­‐
intestinal	   NCGS	   manifestations.	   The	   patient	   identifies	   one	   to	   three	   main	  
symptoms	   that	   will	   be	   quantitatively	   assessed	   using	   a	   Numerical	   Rating	   Scale	  
(NRS)	  with	  a	  score	  ranging	  from	  1	  (mild)	  to	  10	  (severe),	  at	  weeks	  -­‐2,	  -­‐1	  and	  0.	  
At	   time	   0	   a	   strictly	   gluten-­‐free	   baseline	   diet	   is	   started	   after	   detailed	  
explanation	   (preferably	   by	   a	   dietitian).	   Although	   an	   improvement	   of	   the	  
symptoms	   is	   expected	   shortly,	   a	   prolonged	   observation	   is	   needed	   to	   properly	  
investigate	   the	   causal	   relationship,	   particularly	   for	   fluctuating	   symptoms	   (e.g.,	  
headache).	  
At	  least	  six	  weeks	  of	  verified	  GFD	  data	  should	  be	  recorded	  (from	  week	  0	  to	  6),	  
identifying	   one	   to	   three	  main	   symptoms	  weekly.	   Responders	   are	   patients	  who	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fulfill	  the	  response	  criteria	  (>30%	  reduction	  of	  one	  to	  three	  main	  symptoms	  or	  at	  
least	   1	   symptom	   with	   no	   worsening	   of	   others)	   for	   at	   least	   50%	   of	   the	  
observation	  time	  (i.e.,	  at	  least	  three	  of	  six	  weekly	  evaluations).	  	  
Although	  a	  symptomatic	  response	  to	  a	  GFD	  alone	  does	  not	  differentiate	  NCGS	  
and	  CD,	  nor	  should	  it	  be	  used	  to	  diagnose	  CD,	  [28]	  this	  symptom	  improvement	  or	  
cessation,	  as	  well	  as	  their	  reoccurrence	  attributable	  to	  the	  absence	  or	  presence	  
of	   dietary	   gluten,	   is	   highly	   suggestive	   of	   gluten-­‐related	   disorders,	   namely	  
NCGS.[9]	  
The	   diagnosis	   of	   NCGS	   is	   excluded	   in	   subjects	   failing	   to	   show	   symptomatic	  
improvement	   after	   six	   weeks	   of	   GFD	   and	   in	   these	   patients	   it	   should	   be	  
investigated	  other	  possible	  causes	  of	   IBS-­‐like	  symptoms,	  such	  as	   intolerance	   to	  
FODMAPs	  or	  small	  bowel	  bacterial	  overgrowth.	  
After	   a	   GFD,	   an	   amount	   of	   8	   grams	   (with	   pro-­‐inflammatory	   factor	   amylase-­‐
trypsin	  inhibitors	  of	  at	  least	  0.3	  g)	  should	  be	  used	  for	  the	  challenge,	  daily,	  in	  the	  
form	   of	   a	   muesli	   bar,	   bread,	   muffin	   or	   any	   other	   cooked	   baking	   good,	  
homogeneously	  distributed	  with	  gluten.	  The	  placebo	  vehicle	  must	  be	  completely	  
gluten-­‐free	   and	   both	   must	   be	   undistinguishable	   in	   look,	   texture	   and	   taste,	  
FODMAPs	   free	   and	   balanced	   in	   fibers,	   carbohydrate,	   fat	   and	   possibly	   protein	  
content.	  
The	  gluten	  challenge	   includes	  a	  one-­‐week	  challenge	   followed	  by	  a	  one-­‐week	  
washout	  of	   strict	  GFD	  and	  by	   the	   crossover	   to	   the	   second	  one-­‐week	   challenge.	  
The	  duration	  of	  the	  challenge	  period	  may	  occasionally	  be	  longer	  than	  a	  week	  in	  
patients	  showing	  fluctuating	  symptoms.	  	  
The	  same	  questionnaire	  is	  self-­‐administered	  and	  filled,	  daily,	  during	  the	  first	  
seven-­‐day	  challenge	  (or	  less	  if	  symptoms	  prevent	  completion	  of	  seven	  days),	  the	  
washout	   period,	   and	   the	   second	   seven-­‐day	   challenge	   (or	   less).	   During	   the	  
challenge,	   the	   patient	  will	   identify	   and	   report	   one	   to	   three	  main	   symptoms.	   A	  
variation	   of	   at	   least	   30%	   between	   the	   gluten	   and	   the	   placebo	   challenge	  
discriminates	   a	   positive	   from	   a	   negative	   result,	   although	   the	   threshold	   is	  
somewhat	  arbitrary	  and	  needs	  scientific	  validation.	  Patients	  showing	  a	  negative	  
gluten	  challenge	  should	  also	  be	  investigated	  for	  other	  possible	  causes.	  
	  
No	   further	   intervention	   is	   required	   if	   symptoms	   improve	   although	   re-­‐
challenging	   the	   patient	   with	   a	   trial	   of	   gluten-­‐containing	   foods	   in	   the	   future	   is	  
advised,[51]	  as	  there	  is	  always	  the	  possibility	  of	  a	  placebo	  effect.[9,	  61]	  Given	  the	  
difficulties	  of	  maintaining	  a	  GFD,	  not	  only	  because	  gluten-­‐free	   foods	   cost	  more	  
than	  3.5	   times	   the	  price	  of	   gluten-­‐containing	   foods	  with	  no	  proven	   increase	   in	  
nutritional	   value,	   but	   also	   because	   gluten-­‐free	   baked	   goods	   are	   still	   scarce	   in	  
most	   stores	   and	   have	   to	   be	   carefully	   prepared	   at	   home	   or	   by	   specialized	  
bakers,[28]	   it	   may	   be	   reasonable	   to	   first	   make	   general	   dietary	   improvements	  
(more	   fresh	   fruits,	   vegetables,	   whole	   grains,	   and	   non-­‐fried	   low-­‐fat	   sources	   of	  
protein,	  avoiding	  processed	  snack	  foods),	  before	  instituting	  a	  permanent	  GFD.	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Figure	   2	   -­‐	   Diagnostic	   chart	   in	   a	   suspected	   gluten	   related	   disorder.	   HLA	   (Human	   leukocyte	   antigen),	   SPTs/sIgE	   (skin	   prick	  





NCGS	  is	  a	  ‘re-­‐discovered’	  syndrome	  of	  gluten	  intolerance.	  Until	  recently,	  it	  has	  
been	   thought	   to	   be	   typical	   of	   CD	   and	   WA,[8]	   and	   symptomatically	   similar	   to	  
IBS[5]	   but	   it	   is	   in	   fact	   a	   distinct	   clinical	   entity	   characterized	   by	   intestinal	   and	  
extra-­‐intestinal	  symptoms	  related	  to	  the	  ingestion	  of	  gluten-­‐containing	  food.[40]	  
Knowledge	  of	  the	  pathogenesis,	  epidemiology,	  and	  natural	  history	  of	  NCGS	  is	  
still	  quite	  rudimentary	  and	  questions	  remain	  unanswered,	  including	  whether	  the	  
gluten-­‐mediated	  effect	  is	  an	  all-­‐or-­‐none	  or	  a	  dose-­‐related	  phenomenon	  and	  what	  
part	  of	  the	  gluten	  is	  responsible.	  High	  quality,	  well-­‐controlled	  research	  in	  human	  
trials	   is	   difficult	   to	   carry	   out	   and	   is	   fraught	   with	   its	   own	   hurdles	   as	   the	   self-­‐
reported	  NCGS	  patients	  are	  heterogeneous	  in	  their	  range	  of	  reported	  symptoms,	  
clinical	  histories	  and	  characteristics.	  Randomised	  trials	  on	  NCGS	  in	  children	  are	  
also	   lacking[8]	   and	   there	   is	   a	   strong	   clinical	   need	   for	   biomarkers	   in	   the	  
diagnostic	  work-­‐up	  of	  NCGS.[33]	  
Gluten	  avoidance	  can	  have	  an	  impact	  on	  nutritional	  intake	  and	  quality	  of	  life	  
and	  the	  differentiation	  of	  gluten-­‐related	  pathologies	  is	  crucial	  to	  advise	  patients	  
regarding	  the	  importance	  of	  ongoing	  disease	  monitoring,	  a	  required	  GFD,	  and	  for	  
counselling	  and	  testing	  of	  family	  members.[31]	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Important	   considerations	   for	   the	   future	   include	  well-­‐designed	   dietary	   trials	  
investigating	  NCGS	  include	  high	  order	  effects	  in	  cross-­‐over	  designs,	  large	  nocebo	  
effects,	   patient	   selection	   and	   clear	   entry	   criteria,	   methods	   of	   gluten	   challenge,	  
properties	  of	  what	   is	  used	  as	   the	  placebo	  use,	  ensure	  successful	  blinding,	  well-­‐
defined	   endpoints,	   control	   of	   confounding	   dietary	   factors	   and	   trying	   to	   ensure	  
that	  the	  protocol	  and	  provision	  of	  food	  is	  well	  received	  by	  participants.	  	  
Providing	   these	   the	   next	   several	   years	   will	   provide	   a	   stronger	   quality	   of	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